Unless the trend of ever-rising product development costs is reversed, as demonstrated by Eroom’s law (look it up), the development of new biopharmaceutical products is doomed. In my opinion, the primary culprit is the industry’s inability to competently deal with complexity…
JUST PUBLISHED: "Standardized and GMP-Ready, Closed-System Processing of Expanded Adipose-Derived Stem Cells Using the Gibco CTS
Rotea System Across 2D and 3D Bioreactor Expansions." Click on the OPEN ACCESS ARTICLES tab below.
